PMDA drug package insert
ビダーザ注射用100mg
PMDA Prescription drug · 日本新薬株式会社 · package insert Aug 26, 2026
Key facts
| Brand names | ビダーザ注射用100mg |
|---|---|
| Nonproprietary names | アザシチジン |
| Companies | 製造販売元／日本新薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 骨髄異形成症候群 急性骨髄性白血病治療剤 |
| Therapeutic category codes | 874291 |
| YJ codes | 4291419D1026 |
| Approval numbers | 22300AMX00418000 |
| Package insert edition | 第4版 |
| Package insert date | Aug 26, 2026 |
| PMDA document key | 530263_4291419D1026_1 |
| PMDA company code | 530263 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: